Anixa Biosciences, Inc. (ANIX)

Anixa Biosciences Cash Flow Statement

Financials in millions USD. Fiscal year is November - October.

Year Ending	TTM	Oct 31, 2023	Oct 31, 2022	Oct 31, 2021	Oct 31, 2020	Oct 31, 2019
Net Income	-11.6	-9.81	-13.6	-12.95	-10.02	-11.65
Depreciation & Amortization	0.05	0.05	0.04	0.06	0.09	0.05
Share-Based Compensation	4.87	4.51	6.1	7.5	3.92	5.52
Other Operating Activities	-0.5	-0.96	0.96	0.45	-0.17	1.34
Operating Cash Flow	-7.18	-6.21	-6.49	-4.94	-6.18	-4.74
Capital Expenditures	0	0	0	0.04	-0.02	-0.18
Acquisitions	0	0	0	0.01	0	0
Change in Investments	-0.89	-5.6	-10.73	-3.96	-0.29	-0.35
Investing Cash Flow	-0.89	-5.6	-10.73	-3.92	-0.31	-0.53
Share Issuance / Repurchase	6.47	0.37	0.45	31.57	9.41	5.69
Other Financing Activities	-3.03	-	-	-	-	0.01
Financing Cash Flow	3.44	0.37	0.45	31.57	9.41	5.7
Net Cash Flow	-4.63	-11.45	-16.77	22.71	2.93	0.44
Free Cash Flow	-7.18	-6.21	-6.49	-4.9	-6.19	-4.92
Free Cash Flow Margin	-	-2956.67%	-	-957.62%	-	-1966.75%
Free Cash Flow Per Share	-0.23	-0.20	-0.21	-0.17	-0.28	-0.25

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).